Bi-Weekly Cetuximab Combined Chemotherapy For Advanced And Recurrenced Colorectal Cancer

Abstract Cetuximab (Cmab) is human/mouse chimera type monoclonal antibody of IgG1 which assumes EGFR a target, and an effective treatment result is proved for KRAS wild-type advanced/ recurrenced colon cancer. However, the complexity of the dosage method became the problem whereas FOLFOX, the FOLFIRI therapies were every two weeks because the dosage a week was basic in Cmab. In late years there is the report of the space dosage method for Cmab two weeks, too and reports it because I examined safety and the effectiveness of the dosage method in our House for every Cmab2 week. Aims: I examine safety and the effectiveness of the dosage method for every Cmab two weeks in progress recurrence colon cancer. Method: I gave Cmab500mg/m2 in two hours in the first time and gave it after the second in one hour. I decided that the chemotherapy to use together did not matter. Result: As for 20 cases, 13 cases, a woman were seven cases a man. The median age was 71 years old. There were 12 cases in 1st line, 3 cases in 2nd line and 5 cases in 3rd line. This evaluation were partial response were 14 cases, no change were 5 cases and one progressive disease case. For the response rate was 70%, the tumor control rate was 95%. We will calculate progression free and overall survivals. I did not recognize any infusion reaction and over Grade3 paronychia, dry skin and infection as chemotherapy induced adverse events. Discussion: Every 2 weeks infusion of Cmab was as well as every week infusion of Cmab. We thought that he early progressive disease case may have minor mutation of except Codon12,13 in KRAS. I was able to tolerable with the ointment which I prescribed for prophylaxis of tetracycline and the clarithromycin, the part in the side effect of the skin. Conclusion: This method was regarded as one of the effective method in colon cancer chemotherapy.